Bunka Christopher's Form 4 filing
Lexaria Bioscience Corp. (LEXX) · filed Oct 13, 2022
- Accession no.
- 0001855763-22-000014
- Filed
- Oct 13, 2022
- Trade date
- Oct 12-13, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001855763-22-000019 (Oct 18, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bunka ChristopherCIK 0001103780 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2022 | common shares | AGrant or awardAcquired | +21,900 | $1.99 | +$43,581 | 237,812 | Indirect | |
| Oct 13, 2022 | common shares | AGrant or awardAcquired | +16,600 | $2.10 | +$34,860 | 254,412 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.